Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer Inc
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND DMARDS
1. To compare the efficacy of CP-690,550 in doses of 5 mg BID and 10 mg BID versus placebo for the treatment of signs and symptoms of RA in patients with active RA who have had an inadequate response ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
Prevenar Study conducted in Russia
The primary objective is to estimate the incidence of febrile reactions of ≥38 to ≤39°C; >39 to ≤40°C; >40°C occurring within 2 days following vaccination with Prevenar (PCV-7) coadministered with oth...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 4 ans
A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILURE OF ONE PRIOR ANTIANGIOGENIC THERAPY
Primary Objective: To compare the OS of patients with advanced HCC receiving axtitinib + best supportive care (BSC) versus (vs) placebo + BSC following failure of one prior antiangiogenic therapy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC
The primary objective of the maraviroc expanded access program is to facilitate access to maraviroc for subjects, who have limited therapeutic options and to collect safety data in a larger and more d...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc. 235 East 42nd Street, New York, 10017
Update Il y a 4 ans
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB
Primary Objective: • To demonstrate that the combination of sunitinib plus erlotinib is superior to erlotinib plus placebo in prolonging the overall survival for advanced/metastatic NSCLC patients who...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Primary Objective: Demonstrate superior efficacy of tanezumab 10 mg, 5 mg, and 2.5 mg administered IV every 8 weeks in combination with oral diclofenac SR 75 mg BID versus placebo administered IV ev...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
Study to compare on-demand treatment to a prophylaxis regimen of BeneFIX in Hemophilia B subjects with a Factor IX activity:≤2%
The primary objective is to demonstrate that a prophylaxis regimen of BeneFIX reduces the ABR compared to on demand treatment in subjects with moderately severe to severe hemophilia B.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
An 80-week, randomized, multi center, parallel group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer' s disease
The primary objective of this study is to demonstrate the superiority of the effects of combined treatment with atorvastatin plus an acetylcholinesterase inhibitor (donepezil) to treatment with an ace...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN
Demonstrate superior analgesic efficacy of tanezumab 10 mg and 5 mg administered subcutaneously (SC) every 8 weeks compared to placebo at Week 16.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
RANDOMIZED STUDY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS
To compare the efficacy between infliximab-Pfizer and infliximab-EU in subjects with moderately to severely active RA who are treated with infliximab in combination with methotrexate.
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next